White label ELPA - ClinicalTrials.eu

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Recruiting

2 1 1 1
Investigated diseases:
- Bladder cancer
Investigated drugs:
- Durvalumab
BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Recruiting

2 1
Investigated diseases:
- Renal disorder
Investigated drugs:
- [4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
+10
Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting

3 1 1 1
Investigated diseases:
- Chronic myeloid leukaemia
Investigated drugs:
+8
Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Recruiting

3 1 1
Investigated diseases:
- Interstitial lung disease
Investigated drugs:
- Belimumab
+1
Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

Recruiting

2 1
Investigated diseases:
- Myasthenia gravis
Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Recruiting

2 1 1 1
Investigated diseases:
- Epstein-Barr virus infection
Investigated drugs:
- Tenofovir Alafenamide
Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Recruiting

1 1 1 1
Investigated drugs:
- Tocilizumab
BMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer

Recruiting

2 1 1 1
Investigated drugs:
- Nivolumab
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Recruiting

3 1
Investigated diseases:
- Primary progressive multiple sclerosis
+14
JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

Recruiting

3 1 1
Investigated drugs:
- IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
- Teclistamab
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies